Navigation Links
Combo Therapy may Be Highly Beneficial in Asthma Control

A new study has found that combination asthma therapy, SYMBICORT leads to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol or placebo).

SYMBICORT is a recently approved, combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.

SYMBICORT is a combination of two proven asthma medications budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta agonist (LABA).

As part of the 12-week, randomised, double-blind, placebo-controlled, multicenter study, researchers measured HRQL in 553 patients with moderate-to-severe persistent asthma treated with one of five SYMBICORT therapies.

The patients were subjected to two inhalations with SYMBICORT in one pressurised meter-dose inhaler (pMDI) 160/4.5 micrograms (mcg); budesonide pMDI 160 mcg; formoterol via dry-powder inhaler (DPI) 4.5 mcg; budesonide pMDI 160 mcg + formoterol DPI 4.5 mcg in separate inhalers; or placebo, each bid.

HRQL was assessed using the standardised Asthma Quality of Life Questionnaire [AQLQ(S)], a validated survey that measures how asthma affects a person's daily activities, emotional functioning, and symptoms and using patient and physician global assessments.

The study also measured satisfaction to treatment in 390 patients with mild-to-moderate asthma previously treated with inhaled corticosteroids. Patients were randomised to receive treatment with two inhalations with SYMBICORT 80/4.5 mcg, budesonide pMDI 80 mcg, formoterol DPI 4.5 mcg, or placebo, each bid.

Patient satisfaction was assessed using three indices of the Patient Satisfaction with Asthma Medication (PSAM) questi onnaire, which measures relief of symptoms, perception of medication, and comparison with other medications based on a score of 1 (lowest) to 100 (highest).

Researchers found that SYMBICORT led to statistically significant and clinically meaningful improvements in AQLQ(S) scores versus formoterol DPI or placebo. SYMBICORT also significantly improved AQLQ(S) scores, compared with budesonide pMDI on all measures except for emotional function.

Also, SYMBICORT resulted in significantly high satisfaction scores.

The findings of the study were presented at the American Thoracic Society (ATS) 2007 International Conference held in San Francisco.


'"/>




Related medicine news :

1. Drug Combo Works Better for children with ADHD, Tics
2. Scanning Combo Helps Detect Lung Cancer
3. Relief From Asthma With New Combo Therapy
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Drug Combo Improves Performance Of Multiple Sclerosis Drug
6. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
7. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
8. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
9. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
10. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
11. Fuzeon and MK-0518 Combo Holds Promise For HIV
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... ... NuevaCare, a leading home care agency based in San Mateo, California, but ... to announce information upgrades to its blog in the form of WordPress tags. The ... as home care (generally) as well as senior care and home care agency issues. ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation last ... in Neurology Award (PLINA). The couple joins a prestigious list of past PLINA ... Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. , ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: